The estimated Net Worth of Wilhelmus Cm Groenhuysen is at least $19.2 Millón dollars as of 5 June 2024. Mr. Groenhuysen owns over 124,373 units of NovoCure Ltd stock worth over $2,142,947 and over the last 9 years he sold NVCR stock worth over $12,877,460. In addition, he makes $4,187,080 as Chief Operating Officer at NovoCure Ltd.
Wilhelmus has made over 49 trades of the NovoCure Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 124,373 units of NVCR stock worth $2,838,192 on 5 June 2024.
The largest trade he's ever made was exercising 124,373 units of NovoCure Ltd stock on 5 June 2024 worth over $2,838,192. On average, Wilhelmus trades about 15,493 units every 29 days since 2016. As of 5 June 2024 he still owns at least 124,373 units of NovoCure Ltd stock.
You can see the complete history of Mr. Groenhuysen stock trades at the bottom of the page.
Wilhelmus Groenhuysen has been appointed as Chief Operating Officer of the Company effective 9/1/2020. Mr. Groenhuysen has served as the Company's Chief Financial Officer since 2012. He has served on the Board of Optinose Inc., a commercial-stage specialty pharmaceuticals company, since October 2017. From 2007 to 2011, Mr. Groenhuysen worked for Cephalon, Inc., a U.S. biopharmaceutical company, last serving as executive vice president and chief financial officer, where he had responsibility for worldwide finance, commercial operations and risk management. From 1987 to 2007, Mr. Groenhuysen worked for Philips Group in various assignments in Europe, Asia and the United States, the latest of which started in 2002 when he was promoted to chief financial officer and senior vice president of Philips Electronics North America Corporation. Mr. Groenhuysen holds a Master's Degree in Business Economics from VU University Amsterdam and graduated as a Registered Public Controller at VU University Amsterdam.
As the Chief Operating Officer of NovoCure Ltd, the total compensation of Wilhelmus Groenhuysen at NovoCure Ltd is $4,187,080. There are 3 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
Wilhelmus Groenhuysen is 62, he's been the Chief Operating Officer of NovoCure Ltd since 2020. There are 5 older and 17 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
Wilhelmus's mailing address filed with the SEC is C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE, PA, 19087.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... y Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: